Provectus Biopharmaceuticals Inc (NYSE MKT LLC:PVCT)

0.8881
Delayed Data
As of 3:59pm ET
 -0.0319 / -3.47%
Today’s Change
0.30
Today|||52-Week Range
3.75
+11.01%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$170.4M

Company Description

Provectus Biopharmaceuticals, Inc. manufactures prescription drugs, medical device systems and counter products. It is a development-stage biopharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company developing and intend to license or market and sell their two prescription drug candidates, PV-10, which is for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer; and PH-10, which provides minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. Through its subsidiaries, hold patents and other intellectual property related to OTC products and non-core technologies. Provectus Biopharmaceuticals was founded in 2002 and is headquartered in Knoxville, TN.

Contact Information

Provectus Biopharmaceuticals, Inc.
7327 Oak Ridge Highway
Knoxville Tennessee 37931-3488
P:(866) 594-5999
Investor Relations:

Employees

Shareholders

Individual stakeholders6.39%
Mutual fund holders1.67%
Other institutional0.99%

Top Executives

H. Craig DeesChairman & Chief Executive Officer
Timothy C. ScottPresident & Director
Peter R. CulpepperCOO, CFO, Secretary, Treasurer & CAO
Eric A. WachterChief Technology Officer

To view my watchlist

Not a member yet?

Sign up now for a free account